Latest news with #BainCapital
Associated Press
a day ago
- Business
- Associated Press
Faruqi & Faruqi Reminds Cerevel Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options A class action was filed against against Cerevel Therapeutics Holdings, Inc. ('Cerevel' or the 'Company'), Bain Capital Investors, LLC ('Bain') and Pfizer, Inc. ('Pfizer') on behalf of investors that (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ('Exchange Act'); (b) held shares of Cerevel as of January 8, 2024 (the 'Record Date') and were entitled to vote on the merger of Cerevel and AbbVie Inc. ('AbbVie') and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act. If you would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 30, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cerevel Therapeutics Holdings, Inc. ('Cerevel' or the 'Company') (NASDAQ: CERE), Bain Capital Investors, LLC ('Bain') and Pfizer, Inc. ('Pfizer') and reminds investors of the June 3, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See The complaint alleges that the defendants violated federal securities laws by making false and/or misleading statements and/or failing to disclose material facts in connection with Cerevel's October 16, 2023 secondary stock offering at $22.81, in which Cerevel's controlling shareholder, Bain, acquired Cerevel shares while allegedly in possession of material nonpublic information regarding AbbVie's interest in acquiring the Company. Two months later, the Company disclosed the agreement with AbbVie at a price of $45 per share resulting in a windfall for Bain. The complaint alleges that Cerevel's January 18, 2024, Proxy statement for the AbbVie acquisition misled investors regarding the true nature and timing of the sales process and related conflicts, including that the process and October Offering were orchestrated by Bain and Pfizer in order to maximize profits and rush through a sale of the Company even if it was not in the best interest of public shareholders. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Cerevel's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Cerevel class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Forbes
3 days ago
- Business
- Forbes
Fintech Sudden Thaw: What A Cluster Of Rounds Tells Us About Q3 IPOs
Only a few months ago venture capitalists were still calling 2024 a deep-freeze for fintech. Aggregate investment across the sector had fallen more than 70 percent from its pandemic peak, and CB Insights put total global fintech funding in the first quarter of 2025 at just US $10.3 billion—a far cry from the US $38 billion quarters of 2021. Yet in the 10 days between 13 and 23 May the tone flipped. Four mature private companies: Acrisure, Airwallex, Addepar and Bestow, each captured fresh cheques of nine figures or more, together drawing roughly US $2.75 billion. Taken as a set, the deals suggest that the exit window investors dismissed as 'shut' may be inching open just in time for an autumn listing season. The largest splash came first. On 20 May Michigan-based insurtech-cum-financial-services platform Acrisure secured US $2.1 billion in convertible preferred stock led by Bain Capital and Apollo Funds. This round pushed its valuation to US $32 billion, about 40 percent higher than its last mark in 2021. Management says part of the money refinances expensive legacy instruments; the rest funds M&A that will nudge Acrisure beyond brokerage into payroll, cybersecurity, and employee benefits. More revealing was the way CFO Lowell Singer described the raise: 'This gives us balance-sheet clarity ahead of any public-market option.' In banker-speak, that is the equivalent of pointing at the S-1 stack on the corner of the desk. Hours later, Airwallex—founded in Melbourne, headquartered in Singapore—announced a US $300 million Series F at a US $6.2 billion valuation. Half the round was secondary, handing early employees and angels long-sought liquidity, but the primary tranche brings the company's total funding to more than US $1.2 billion. Airwallex now processes payments in 60 countries, tracking toward US $1 billion in annualised revenue for 2025. Co-founder Jack Zhang called the up-round an 'important milestone on our path to the public markets,' adding that he wants at least two EBITDA-positive quarters before filing. A day later wealth-tech platform Addepar revealed a US $230 million Series G that values it at US $3.25 billion. More than half the proceeds go to a tender offer for long-time shareholders, house-cleaning that venture lawyers typically advise before a company flips its registration. Addepar now claims US $7 trillion of client assets on its analytics stack and insists it will be profitable in 2025. Finally, Dallas-based insurtech Bestow closed an oversubscribed US $120 million Series D co-led by Goldman Sachs Alternatives and Smith Point Capital, plus a US $50 million credit facility from TriplePoint. Bestow divested its consumer life-insurance carrier last year and now licenses underwriting software to incumbents, a pivot that tripled annual recurring revenue in 2024 and, according to CEO Melbourne O'Banion, turned the firm 'cash-flow neutral on a run-rate basis.' Four data points do not make a trend, but they do cluster around a narrative: late-stage investors have decided that fintech companies with real revenue, global footprints and near-term profitability can once again command large cheques at flat-to-up valuations. Several forces are converging. First, capital concentration. Limited partners are pressuring growth funds to deploy cash that has been sitting, fee-dragging, in drawdown notices. Instead of sprinkling Series B bets, those funds are writing fewer, larger tickets into businesses that can plausibly go public inside two years. Acrisure's raise alone absorbs pockets of dry powder that might otherwise have been scattered across a dozen smaller rounds. Second, profit visibility has become the gating item for every term sheet. All four firms either print black ink already or forecast it within 12 months. Airwallex's FX spread actually widens when the US dollar surges, providing a natural hedge against higher rates. Acrisure throws off cash from a traditional brokerage arm. Addepar skates on software-as-a-service margins. Investors no longer have to squint to see operating leverage. Third, secondary liquidity is back in fashion. Airwallex and Addepar earmarked roughly half of their rounds for early employee or seed-fund liquidity, a move that only makes sense if buyers believe they can recycle shares through an IPO at a premium within 18 to 24 months. Venture secondary specialists confirm that secondary prints have tightened from 60 percent discounts to low double-digits on marquee names. Finally, public-market tone has brightened, if only at the margins. On 8 May, Apollo-owned Aspen Insurance raised US $397 million in the largest US insurance IPO since 2022; shares popped 11 percent on day one. Investors looking for recession-resilient cash flow found it in sectoral plays like specialty insurance, and that is exactly the pitch Acrisure will make when it comes knocking. Bankers who worked on the recent rounds say file-ready documentation is already circulating. Acrisure has sounded out bulge-bracket banks for a dual-track that could see a confidential filing as early as July. Airwallex insiders point to October as the first window, contingent on two consecutive profitable quarters and the completion of licensing in Japan and the UAE. Addepar's tender offer paperwork explicitly notes that 'liquidity alternatives, including a potential initial public offering, may be pursued within a reasonable horizon.' If even two of the quartet launch roadshows, they will join a backlog of mature fintechs—Stripe, Rapyd, Nium, Klarna, Monzo, waiting for underwriting desks to reopen. Momentum breeds momentum: each successful float provides price discovery that the next issuer can cite, widening the aperture a little more. Private investors are once again paying forward for growth, though they remain more conservative than in 2021. At ≈5.5 × projected 2025 revenue, Airwallex's post-money multiple is richer than Wise, which trades around 3 × on the London Stock Exchange, but lower than the frothy nine-times prints of 2021. Acrisure's ≈12 × EBITDA multiple sits between listed brokerage Brown & Brown and pure-play insurtech Lemonade, which still languishes below book. Addepar's ≈11 × ARR is healthy but not outrageous next to Bloomberg's implied 15 × private-market valuation. Plenty. A move by the Federal Reserve or the Trump Administration that sends the ten-year Treasury back above five percent would sap risk appetite faster than any venture round can close. Regulatory curve-balls also loom. Acrisure's diversification into cyber and payments invites capital-adequacy scrutiny; Airwallex still has to complete multi-jurisdiction licensing across four continents before public investors will underwrite geopolitical risk. And an overcrowded IPO calendar can force valuation haircuts if buy-side funds lack bandwidth to diligence every deal. Clustered activity does not guarantee a full-blown spring. It does, however, mark the first time since late 2021 that growth-stage fintechs have raised multi-hundred-million-dollar rounds at higher valuations and funnelled meaningful cash to secondary sellers. That only happens when investors see a clear exit path. For founders, the signal is clear: if you can show real revenue growth, a short march to profitability and a plausible public-market comp, capital is once again on the table. For public-equity investors, a gentle warning: the pipeline is lining up. The window many declared shut is at least ajar, and if markets hold steady through the summer, Q3 could bring the busiest fintech IPO season in three years, one megadeal at a time. If Aspen's modest float was the starter pistol, the funding flurry of late May may prove to be the warm-up lap. Whether the race truly begins this autumn will depend on macro stability, but for the first time in a long while, fintech's next class of public companies is stepping up to the blocks.
Associated Press
4 days ago
- Business
- Associated Press
CERE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important June 3 Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - May 27, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the 'Class Period'); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023, of the important June 3, 2025 lead plaintiff deadline. SO WHAT: If you sold and/or held Cerevel common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Cerevel class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements in connection with Cerevel's October 16, 2023 secondary stock offering and in its January 18, 2024 proxy statement. As alleged in the complaint, the secondary stock offering was orchestrated by Cerevel's controlling shareholders, Bain Capital, LP and Pfizer Inc., to allow Bain to increase its position in Cerevel at a deeply discounted price in advance of AbbVie Inc.'s undisclosed forthcoming acquisition of Cerevel. Just 51 days after the offering, Cerevel publicly announced that AbbVie agreed to acquire Cerevel for $45 per share - i.e., nearly double the offering price - and Bain's discounted purchases from the offering resulted in it receiving a windfall of more than $120 million. To join the Cerevel class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
Yahoo
4 days ago
- Business
- Yahoo
India's 360 One plans to set up investment banking vertical
Indian wealth management company 360 One is set to expand its investment banking operations, reported Financial Express. The firm aims to build the investment banking vertical through Batlivala & Karani (B&K), a brokerage it acquired in January. B&K is known for its institutional brokerage. Mumbai-based 360 One, already holding an investment banking licence from SEBI, plans to expand B&K's small merchant banking operations into a full-service investment bank. The company, which has R5.79tn ($68bn) in assets under management, is also on the verge of closing four investment funds, according to a senior executive. These include a healthcare fund ranging from Rs7bn-Rs10bn, an angel fund of Rs5bn targeting domestic startups, a multi-asset fund for listed stocks, and a private credit fund of $8bn. The angel fund has already invested in a gaming company and a chilli sauce maker. In 2024, 360 One closed a R40bn secondary fund focused on the private equity landscape. The firm is majority-owned by Bain Capital since 2022 and has offices in Dubai and Singapore. As of March, foreign portfolio investors hold 67.2% of 360 One, with mutual funds owning 6.4% and total domestic institutional investor ownership at 8.5%. The company was listed on the BSE and NSE in 2019. In 2024, it acquired ET Money from Bennet Coleman and raised Rs22.5bn through a qualified institutional placement. Managing director and promoter Karan Bhagat holds a 14.2% stake, with half pledged. Investment banking in India is currently dominated by foreign banks and brokerages such as Citi, JP Morgan, Deutsche, Morgan Stanley, and UBS, with Kotak, SBI Caps, Axis Capital, JM Financial, and Edelweiss as key domestic players. Founded in 2008, 360 One made a deal with Swiss banking giant UBS in April, facilitated by Bain Capital. The firm agreed to acquire a Rs260bn wealth portfolio from UBS for $36m, while UBS agreed take a nearly a 5% stake in 360 One for $220m. The integration of the UBS wealth portfolio with 360 One is pending regulatory approval. Last week, UBS sought approval from the fair trade regulator CCI to acquire the stake in 360 One. "India's 360 One plans to set up investment banking vertical " was originally created and published by Private Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
6 days ago
- Business
- Associated Press
CERE DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action
NEW YORK, May 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the 'Class Period'); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023, of the important June 3, 2025 lead plaintiff deadline. SO WHAT: If you sold and/or held Cerevel common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Cerevel class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements in connection with Cerevel's October 16, 2023 secondary stock offering and in its January 18, 2024 proxy statement. As alleged in the complaint, the secondary stock offering was orchestrated by Cerevel's controlling shareholders, Bain Capital, LP and Pfizer Inc., to allow Bain to increase its position in Cerevel at a deeply discounted price in advance of AbbVie Inc.'s undisclosed forthcoming acquisition of Cerevel. Just 51 days after the offering, Cerevel publicly announced that AbbVie agreed to acquire Cerevel for $45 per share – i.e., nearly double the offering price – and Bain's discounted purchases from the offering resulted in it receiving a windfall of more than $120 million. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Cerevel class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
